Gate2Brain was founded in 2020 as a result of research devoted to peptides with the capacity to cross the Blood-Brain Barrier (BBB) and simultaneously carry therapeutic molecules. The flagship product, G2B-001, is a promising therapy for a paediatric brain tumour, for which there is no cure.
Image
